Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
PARSIPPANY, N.J. and TEL AVIV, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the submis
3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
09:26am, Monday, 08'th Dec 2025
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
08:52am, Saturday, 06'th Dec 2025
Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions.
Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
02:08pm, Thursday, 04'th Dec 2025
Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Mark Cuban Takes Aim at FDA Fees
02:08pm, Thursday, 04'th Dec 2025
Viatris (VTRS) and Teva Pharma (TEVA) could soon face fresh competition after billionaire entrepreneur Mark Cuban called on Washington to scrap a fee he says is
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
10:40am, Tuesday, 02'nd Dec 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks
03:14am, Sunday, 30'th Nov 2025
Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarte
Suite aux avis favorables rendus par le Comité des médicaments à usage humain (CMUH), la Commission européenne a accordé des autorisations de mise en marché visant les biosimilaires PONLIMSI et
Aufgrund der positiven Stellungnahmen des Ausschusses für Humanarzneimittel (CHMP) hat die Europäische Kommission die Zulassungen für die Biosimilars PONLIMSI und DEGEVMA von Teva erteilt und damit
Larry Robbins' Strategic Acquisition of Butterfly Network Inc. Shares
02:01pm, Tuesday, 25'th Nov 2025
Significant Transaction by Glenview Capital Management On November 21, 2025, Larry Robbins (Trades, Portfolio), through Glenview Capital Management, executed a
TEL AVIV, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced that the European Comm
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He's Buying Now.
11:38am, Monday, 24'th Nov 2025
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing.
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of execu
Teva seeks startups to help solve global pharmaceutical challenges
08:07am, Wednesday, 19'th Nov 2025
Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global pharmaceutical
Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript
08:58am, Tuesday, 18'th Nov 2025
Teva Pharmaceutical Industries Limited ( TEVA ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants Richard Francis - President, CEO & Director Conference Ca
